Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease
Maria Vittoria Dieci(Istituto Oncologico Veneto), Valentina Guarneri(Istituto Oncologico Veneto), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico), Federica Miglietta(University of Padua), Elisabetta Di Liso(Istituti di Ricovero e Cura a Carattere Scientifico), Grazia Maria Vernaci(University of Padua), Giulia Tasca(University of Padua), Vassilena Tsvetkova(University of Padua), Alice Menichetti(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Giovanni Faggioni(Istituto Oncologico Veneto), Enrico Orvieto(AULSS 2 Marca Trevigiana), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Mara Mantiero(University of Padua), Gaia Griguolo(University of North Carolina at Chapel Hill), Tania Saibene(Istituti di Ricovero e Cura a Carattere Scientifico), Enrico Cumerlato(University of Padua), Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), Simona Frezzini(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 71
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226